---
layout: post
title: "Prospective Grant of an Exclusive Patent License: The Development of Bispecific Antibodies Targeting Glypican 1 (GPC1) for the Treatment of GPC1-Expressing Human Cancer"
date: 2026-02-05 19:09:15 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-06917
original_published: 2020-04-02 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: The Development of Bispecific Antibodies Targeting Glypican 1 (GPC1) for the Treatment of GPC1-Expressing Human Cancer

**Published:** February 05, 2026 19:09 UTC
**Source:** Federal Register
**Original Published:** April 02, 2020 00:00 UTC
**Document Number:** 2020-06917

## Summary

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to NeoImmune Tech, Inc. (NeoImmune), located in Rockville, Maryland.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/04/02/2020-06917/prospective-grant-of-an-exclusive-patent-license-the-development-of-bispecific-antibodies-targeting)
- API: https://www.federalregister.gov/api/v1/documents/2020-06917

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
